WO1995020955A1 - Liquid pharmaceutical compositions comprising thyroid hormones - Google Patents
Liquid pharmaceutical compositions comprising thyroid hormones Download PDFInfo
- Publication number
- WO1995020955A1 WO1995020955A1 PCT/EP1995/000323 EP9500323W WO9520955A1 WO 1995020955 A1 WO1995020955 A1 WO 1995020955A1 EP 9500323 W EP9500323 W EP 9500323W WO 9520955 A1 WO9520955 A1 WO 9520955A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- thyroid hormone
- volume
- pharmaceutically acceptable
- ethanol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK95908224T DK0742714T3 (en) | 1994-02-01 | 1995-01-30 | Liquid pharmaceutical preparations comprising thyroid hormones |
AU16631/95A AU1663195A (en) | 1994-02-01 | 1995-01-30 | Liquid pharmaceutical compositions comprising thyroid hormones |
DE69520492T DE69520492T2 (en) | 1994-02-01 | 1995-01-30 | LIQUID MEDICINAL PREPARATIONS CONTAINING THYROID HORMONES |
EP95908224A EP0742714B1 (en) | 1994-02-01 | 1995-01-30 | Liquid pharmaceutical compositions comprising thyroid hormones |
US08/682,779 US6458842B1 (en) | 1994-02-01 | 1995-01-30 | Liquid pharmaceutical compositions comprising thyroid hormones |
AT95908224T ATE200025T1 (en) | 1994-02-01 | 1995-01-30 | LIQUID MEDICINAL PREPARATIONS CONTAINING THYROID HORMONES |
GR20010400554T GR3035706T3 (en) | 1994-02-01 | 2001-04-05 | Liquid pharmaceutical compositions comprising thyroid hormones |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9401891.8 | 1994-02-01 | ||
GB9401891A GB9401891D0 (en) | 1994-02-01 | 1994-02-01 | Therapeutic agents |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/682,779 A-371-Of-International US6458842B1 (en) | 1994-02-01 | 1995-01-30 | Liquid pharmaceutical compositions comprising thyroid hormones |
US10/243,555 Division US6706255B2 (en) | 1994-02-01 | 2002-09-13 | Liquid pharmaceutical compositions comprising thyroid hormones |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995020955A1 true WO1995020955A1 (en) | 1995-08-10 |
Family
ID=10749668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/000323 WO1995020955A1 (en) | 1994-02-01 | 1995-01-30 | Liquid pharmaceutical compositions comprising thyroid hormones |
Country Status (14)
Country | Link |
---|---|
US (3) | US6458842B1 (en) |
EP (1) | EP0742714B1 (en) |
AT (1) | ATE200025T1 (en) |
AU (1) | AU1663195A (en) |
CA (1) | CA2182037A1 (en) |
DE (1) | DE69520492T2 (en) |
DK (1) | DK0742714T3 (en) |
ES (1) | ES2155124T3 (en) |
GB (1) | GB9401891D0 (en) |
GR (1) | GR3035706T3 (en) |
IL (1) | IL112516A0 (en) |
PT (1) | PT742714E (en) |
WO (1) | WO1995020955A1 (en) |
ZA (1) | ZA95743B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003041699A1 (en) * | 2001-11-13 | 2003-05-22 | Mylan Pharmaceuticals Inc. | Storage stable thyroxine active drug formulations and methods for their production |
US6645526B2 (en) | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
WO2005009433A1 (en) * | 2003-07-24 | 2005-02-03 | Fernando Goglia | Use of 3,5 diiodothyronine as regulators of lipid metabolism |
JP2009522335A (en) * | 2006-01-06 | 2009-06-11 | インターベツト・インターナシヨナル・ベー・ベー | Concentrated liquid thyroid hormone composition |
EP3261676A4 (en) * | 2015-02-27 | 2018-10-17 | Parikh, Nilesh | Liquid levothyroxine formulations |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9401891D0 (en) * | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
US6501188B1 (en) * | 1997-07-03 | 2002-12-31 | Micron Technology, Inc. | Method for improving a stepper signal in a planarized surface over alignment topography |
US20030095927A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
US20030190286A1 (en) * | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
US20050180923A1 (en) * | 1997-10-01 | 2005-08-18 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing testosterone |
US20030077228A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
US20030095925A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
US20050287075A1 (en) * | 1997-10-01 | 2005-12-29 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20050002867A1 (en) * | 1997-10-01 | 2005-01-06 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
EP1029536B1 (en) * | 1997-10-01 | 2007-11-28 | Novadel Pharma Inc. | Buccal non-polar spray |
US20040136914A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing ondansetron |
US7632517B2 (en) * | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US20040136915A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
US20090162300A1 (en) * | 1997-10-01 | 2009-06-25 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing alprazolam |
US20040141923A1 (en) * | 1997-10-01 | 2004-07-22 | Dugger Harry A. | Buccal, polar and non-polar spray containing alprazolam |
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20050281752A1 (en) * | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20040136913A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing sumatriptan |
US7018654B2 (en) | 1999-03-05 | 2006-03-28 | New River Pharmaceuticals Inc. | Pharmaceutical composition containing an active agent in an amino acid copolymer structure |
US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US7060708B2 (en) * | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US7163918B2 (en) | 2000-08-22 | 2007-01-16 | New River Pharmaceuticals Inc. | Iodothyronine compositions |
US20020099013A1 (en) * | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
US20030198671A1 (en) * | 2001-08-10 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique plasma AUC properties |
US20070066537A1 (en) * | 2002-02-22 | 2007-03-22 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US7338939B2 (en) * | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US7375082B2 (en) * | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
US20060014697A1 (en) | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
US20040043066A1 (en) * | 2001-10-29 | 2004-03-04 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Tmax properties |
US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
IL163668A0 (en) * | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Use of peptide-drug conjugation to reduce inter-subject variability ofdrug serum levels |
US7659253B2 (en) * | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
ES2500117T3 (en) * | 2002-02-22 | 2014-09-30 | Shire Llc | Novel sustained release pharmaceutical compounds to prevent the abuse of controlled substances |
US7700561B2 (en) * | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
WO2004041208A2 (en) * | 2002-11-05 | 2004-05-21 | New River Pharmaceuticals Inc. | Controlled absorption of mixed thyroyd hormone formulations |
KR101170840B1 (en) * | 2003-05-29 | 2012-08-03 | 샤이어 엘엘씨 | Abuse resistant amphetamine compounds |
EP1675555A4 (en) * | 2003-09-30 | 2011-03-09 | Shire Llc | Pharmaceutical compositions for prevention of overdose or abuse |
EP2015632B1 (en) * | 2006-04-19 | 2015-12-02 | Mist Pharmaceuticals, LLC | Stable hydroalcoholic oral spray formulations and methods |
CA2673049C (en) * | 2006-12-22 | 2016-02-23 | Novadel Pharma Inc. | Stable anti-nausea oral spray formulations and methods |
CN101801346A (en) * | 2007-05-10 | 2010-08-11 | 诺瓦德尔药品公司 | anti-insomnia compositions and methods |
US7985325B2 (en) * | 2007-10-30 | 2011-07-26 | Novellus Systems, Inc. | Closed contact electroplating cup assembly |
DK2683361T3 (en) * | 2011-03-10 | 2016-02-01 | Emp Pharma Gmbh | Process for preparing a levothyroxine solution |
GR1008017B (en) | 2012-08-03 | 2013-10-24 | Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδας, Εμπορια Φαρμακων, | Preparation of drinkable solution of levothyroxine or pharmaceutically acceptable salt thereof |
EP3311844A1 (en) | 2016-10-18 | 2018-04-25 | Altergon S.A. | High-stability packaged solutions of t4 thyroid hormone |
US9782376B1 (en) | 2016-12-01 | 2017-10-10 | Fresenius Kabi Usa Llc | Levothyroxine liquid formulations |
US11241382B2 (en) | 2019-03-01 | 2022-02-08 | Altergon Sa | Administration regimen of compositions of T4 thyroid hormone with high oral absorption |
WO2022221480A1 (en) * | 2021-04-15 | 2022-10-20 | Vertice Pharma Llc | Stable liquid oral dosage forms of liothyronine |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB923171A (en) * | 1959-05-01 | 1963-04-10 | Smith Kline French Lab | Anti-hypercholesterolemic compositions comprising dí¬3,5,3-triiodothyronine |
DE2546474A1 (en) * | 1975-10-17 | 1977-04-21 | Murray M D Israel | Cholesterol-lowering thyroxine parenteral preparations - also contg. vitamin B12 to eliminate side effects |
GB2191695A (en) * | 1986-06-13 | 1987-12-23 | Univ Tianjin | Ophtalmic compositions containing thyroid hormones |
JPS6379824A (en) * | 1986-09-24 | 1988-04-09 | Advance Co Ltd | Carcinostatic agent |
JPH06183952A (en) * | 1992-12-18 | 1994-07-05 | Sanyo Chem Ind Ltd | Aqueous solution of thyroid hormone |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA680863A (en) | 1964-02-25 | G. Ginger Leonard | Compositions containing d-isomers of thyronine | |
US3090724A (en) | 1961-01-03 | 1963-05-21 | Baxter Laboratories Inc | Method of treating dermatological conditions |
DE2126533A1 (en) | 1971-05-28 | 1972-12-14 | Merck Patent Gmbh, 6100 Darmstadt | Process for the production of pharmaceutical preparations |
GB8501372D0 (en) * | 1985-01-18 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
US4904697A (en) * | 1987-04-09 | 1990-02-27 | Merrell Dow Pharmaceuticals Inc. | Controlling the growth of certain tumor tissue with chalcone derivatives |
US5158978A (en) * | 1990-02-05 | 1992-10-27 | British Technology Group (U.S.A.) | Thyroid hormone treatment of acute cardiovascular compromise |
US5571840A (en) * | 1993-06-22 | 1996-11-05 | The Regents Of The University Of Michigan | Method for treating central nervous system ischemia |
GB9401891D0 (en) * | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
US5635209A (en) * | 1995-10-31 | 1997-06-03 | Vintage Pharmaceuticals, Inc. | Stabilized composition of levothyroxine sodium medication and method for its production |
-
1994
- 1994-02-01 GB GB9401891A patent/GB9401891D0/en active Pending
-
1995
- 1995-01-30 WO PCT/EP1995/000323 patent/WO1995020955A1/en active IP Right Grant
- 1995-01-30 DE DE69520492T patent/DE69520492T2/en not_active Expired - Fee Related
- 1995-01-30 PT PT95908224T patent/PT742714E/en unknown
- 1995-01-30 AT AT95908224T patent/ATE200025T1/en not_active IP Right Cessation
- 1995-01-30 EP EP95908224A patent/EP0742714B1/en not_active Expired - Lifetime
- 1995-01-30 AU AU16631/95A patent/AU1663195A/en not_active Abandoned
- 1995-01-30 CA CA002182037A patent/CA2182037A1/en not_active Abandoned
- 1995-01-30 ES ES95908224T patent/ES2155124T3/en not_active Expired - Lifetime
- 1995-01-30 US US08/682,779 patent/US6458842B1/en not_active Expired - Fee Related
- 1995-01-30 DK DK95908224T patent/DK0742714T3/en active
- 1995-01-31 ZA ZA95743A patent/ZA95743B/en unknown
- 1995-02-01 IL IL11251695A patent/IL112516A0/en unknown
-
2001
- 2001-04-05 GR GR20010400554T patent/GR3035706T3/en not_active IP Right Cessation
-
2002
- 2002-09-13 US US10/243,555 patent/US6706255B2/en not_active Expired - Fee Related
-
2004
- 2004-03-15 US US10/802,659 patent/US20040266877A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB923171A (en) * | 1959-05-01 | 1963-04-10 | Smith Kline French Lab | Anti-hypercholesterolemic compositions comprising dí¬3,5,3-triiodothyronine |
DE2546474A1 (en) * | 1975-10-17 | 1977-04-21 | Murray M D Israel | Cholesterol-lowering thyroxine parenteral preparations - also contg. vitamin B12 to eliminate side effects |
GB2191695A (en) * | 1986-06-13 | 1987-12-23 | Univ Tianjin | Ophtalmic compositions containing thyroid hormones |
JPS6379824A (en) * | 1986-09-24 | 1988-04-09 | Advance Co Ltd | Carcinostatic agent |
JPH06183952A (en) * | 1992-12-18 | 1994-07-05 | Sanyo Chem Ind Ltd | Aqueous solution of thyroid hormone |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, vol. 121, no. 18, 31 October 1994, Columbus, Ohio, US; abstract no. 213005 * |
DATABASE WPI Week 8820, Derwent World Patents Index; AN 88-137257 (20) * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003041699A1 (en) * | 2001-11-13 | 2003-05-22 | Mylan Pharmaceuticals Inc. | Storage stable thyroxine active drug formulations and methods for their production |
US6645526B2 (en) | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
US7052717B2 (en) | 2001-11-13 | 2006-05-30 | Mylan Pharmaceuticals Inc. | Storage stable thyroxine active drug formulations and methods for their production |
WO2005009433A1 (en) * | 2003-07-24 | 2005-02-03 | Fernando Goglia | Use of 3,5 diiodothyronine as regulators of lipid metabolism |
JP2009522335A (en) * | 2006-01-06 | 2009-06-11 | インターベツト・インターナシヨナル・ベー・ベー | Concentrated liquid thyroid hormone composition |
US8318712B2 (en) | 2006-01-06 | 2012-11-27 | Intervet International B.V. | Concentrated liquid thyroid hormone composition |
EP3261676A4 (en) * | 2015-02-27 | 2018-10-17 | Parikh, Nilesh | Liquid levothyroxine formulations |
Also Published As
Publication number | Publication date |
---|---|
DK0742714T3 (en) | 2001-04-30 |
DE69520492T2 (en) | 2001-07-12 |
EP0742714A1 (en) | 1996-11-20 |
US20040266877A1 (en) | 2004-12-30 |
IL112516A0 (en) | 1995-12-08 |
ZA95743B (en) | 1995-08-01 |
ATE200025T1 (en) | 2001-04-15 |
GB9401891D0 (en) | 1994-03-30 |
US6458842B1 (en) | 2002-10-01 |
PT742714E (en) | 2001-08-30 |
EP0742714B1 (en) | 2001-03-28 |
DE69520492D1 (en) | 2001-05-03 |
US6706255B2 (en) | 2004-03-16 |
AU1663195A (en) | 1995-08-21 |
CA2182037A1 (en) | 1995-08-10 |
US20030130351A1 (en) | 2003-07-10 |
ES2155124T3 (en) | 2001-05-01 |
GR3035706T3 (en) | 2001-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0742714B1 (en) | Liquid pharmaceutical compositions comprising thyroid hormones | |
RU2203655C2 (en) | Agent and method for relieve of sick throat symptoms | |
CA2333528C (en) | A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer | |
HU211937A9 (en) | Indole derivatives | |
EP0183527A2 (en) | Absorbable calcitonin medicament | |
GB2142820A (en) | Aqueous compositions of ranitidine | |
JP3597333B2 (en) | Pharmaceutical preparations for treating acute rhinitis | |
HU192246B (en) | Process for producing of galenic compositions consisting of calcitonin | |
CA2659245A1 (en) | Anti-migraine oral spray formulations and methods | |
EP0069600A2 (en) | Pharmaceutical compositions | |
HUP0105173A2 (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
US20080221144A1 (en) | Controlled Release Formulations | |
WO2001008662A1 (en) | Liquid pharmaceutical composition based on paracetamol | |
JPH01246221A (en) | Phenol-containing antitussive agent | |
GB1487334A (en) | Pharmaceutical preparations comprising lisuride and/or physiologically tolerable salts thereof | |
JP3470901B2 (en) | Method for inhibiting Elf5A biosynthesis | |
US20230293625A1 (en) | Method for treating gingivitis and gingival atrophy and repairing oral mucosa | |
JPH10259132A (en) | Aqueous suspension for nasal drop | |
JPH085784B2 (en) | Syrup | |
GB2177915A (en) | Oral hygiene compositions | |
IE893502L (en) | Formulations | |
RU2001116587A (en) | IMPROVEMENT OF CHARACTERISTICS OF ISOLATION OF ACTIVE MEDICINAL COMPONENTS FROM THE CHEWING RUBBER CASING | |
IE832339L (en) | Liquid nasal pharmaceutical composition | |
TH20304EX (en) | Controlled release formula containing tramadol | |
IT9048064A1 (en) | CALCITONIN-BASED PHARMACEUTICAL COMPOSITIONS ADMINISTRABLE BY NASAL WAY IN HUMAN THERAPY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2182037 Country of ref document: CA Ref document number: 1995908224 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08682779 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1995908224 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995908224 Country of ref document: EP |